Adimmune Corporation is a vaccine and biologics manufacturer founded in 1965. The company produces trivalent and quadrivalent influenza vaccines, Japanese Encephalitis Vaccine, Tetanus Toxoid, and purified Tuberculin. It operates as a contract development and manufacturing organization (CDMO), providing collaborative development, technical cooperation, filling and packaging services, and regulatory support. Adimmune supports Sanofi Pasteur in the commercialization of recombinant protein quadrivalent influenza vaccines in the United States and cooperates with Shenzhen Techdow to produce low-molecular enoxaparin sodium. The company has engaged in technical cooperation with Kitasato Daiichi Sankyo and Crucell, and signed a memorandum of understanding with Becton Dickinson. Its products are supplied to markets in Taiwan, China, and Southeast Asia, and it participates in the WHO Pandemic Influenza Preparedness Framework.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Drug Manufacturers - General Homepage adimmune.com.tw
Sector Healthcare IR page adimmune.com.tw/en/investor
Tags
vaccines, biologics, contract manufacturing, influenza vaccines, tetanus vaccines, cell culture, aseptic filling, regulatory support, AdimFlu-S, Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Influenza A (H1N1) Virus Monovalent Vaccine, Japanese Encephalitis Vaccine, Tetanus Toxoid, purified Tuberculin, Kitasato Daiichi Sankyo, Crucell, Becton Dickinson, Sanofi Pasteur, Shenzhen Techdow
Press page adimmune.com.tw/en/news

Metrics

Valuation  
Market cap NT$ 6.679B
Market cap (USD) $ 202.712M
P/E 93.24
PEG —
P/BV 1.38
P/S 4.15
P/OCF 9.99
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE -4.7%
ROI -4.9%
ROIC -5.5%
Profit margin -17.1%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -56.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 1.402B 1.557B 1.785B 2.252B 1.641B 1.869B 1.3B 822.366M 562.743M 606.725M 290.737M 480.506M 414.093M
Net profit -239.889M -242.75M -639.891M 290.975M 43.066M 1.241B -280.678M -609.117M -760.176M -595.352M -761.087M -614.422M -600.453M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 18.95 20.1 33.15 35.6 44.65 56.1 — — — — — — —
Price performance 12m -0.06 -0.39 -0.07 -0.2 -0.2 — — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Adimmune Corporation (ticker 4142.TW), listed in Taiwan.

ETFs Holding Adimmune Corporation

ETF Weight in ETF Shares Market value As of
AVEE 0.01% 27,000 $ 13.384K Nov 16, 2026
DFEM 0.00% 441,000 $ 223.379K Nov 12, 2026
DFAE 0.00% 271,000 $ 137.269K Nov 12, 2026
DEXC 0.00% 7,000 $ 3,545.70 Nov 12, 2026
DFAX 0.00% 223,000 $ 112.956K Nov 12, 2026